European Conditional Marketing Authorization – Does Early Marketing Authorization Translate Into Early Reimbursement And Patient Access?

October 4, 2018 Danielle Twigg

Since 2006, the European Commission has granted Conditional Marketing Authorizations (CMAs) for medicines where the benefit of immediate availability outweighs the risk of less comprehensive data than normally required in cases of severe/life-threatening disease, emergency situations or orphan medicines. However, to reach patients, medicines must also be publically reimbursed. This research aims to assess the reimbursement outcomes of major public payer bodies of all medicines approved under CMAs.

Authors: Macaulay R, Sutcliffe D, PAREXEL International, London, United Kingdom

To find out more about this poster you can register to download it here after the ISPOR event.

 

 

Previous Article
Moving From The Regulator To The Payer And Prescriber
Moving From The Regulator To The Payer And Prescriber

Next Article
RCT Not RWE: Two Year Report Card For The Cancer Drugs Fund Reforms
RCT Not RWE: Two Year Report Card For The Cancer Drugs Fund Reforms